NeuroBo Pharmaceuticals' MetaVia Announces Reverse Stock Split to Secure Nasdaq Listing Compliance

MetaVia Inc. Implements Reverse Stock Split to Maintain Nasdaq Listing

MetaVia Inc. announces a strategic move aimed at ensuring its compliance with Nasdaq's listing requirements by implementing a 1-for-11 reverse stock split, effective December 4, 2025. This decision follows the approval from stockholders during the company’s annual meeting held on June 30, 2025. The reverse stock split is a common maneuver utilized by companies to enhance their stock price and reduce the number of outstanding shares, thereby improving their market perception. By consolidating 11 shares into one, MetaVia reduces its outstanding shares from approximately 25.4 million to about 2.3 million, while maintaining its total authorized shares at 100 million.

The reverse stock split is designed to help MetaVia align with Nasdaq's minimum bid price requirements, which is crucial for its continued listing on the exchange. The adjustment in the share structure does not affect the company's total par value or the overall equity stake of shareholders, as the total value of their holdings remains unchanged despite the reduced number of shares. Furthermore, the move recalibrates the conversion and exercise prices for outstanding stock options, restricted stock units, and warrants, ensuring fairness for current shareholders while complying with regulatory stipulations.

In addition to the logistical changes, any fractional shares resulting from the reverse split will be rounded down to the nearest whole share, with shareholders receiving cash equivalent to the market value of any fractional shares. This comprehensive strategy underscores MetaVia's commitment to maintaining its operational stability and regulatory compliance, enabling the company to focus on its core mission of developing innovative solutions for cardiometabolic diseases.

In a related note, this reverse stock split reflects broader trends in the biotech sector, where companies frequently take similar actions to navigate the stock market's complexities. Maintaining a strong presence on major exchanges like Nasdaq is essential for attracting investment and fostering growth in an industry characterized by rapid advancements and intense competition. As MetaVia prepares for the implementation of this split, stakeholders remain optimistic about the company's prospects in the cardiometabolic landscape.